Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=71 Vaper to Vaper: A Multimodal Mobile Peer Driven Intervention to Support Adolescents in Quitting Vaping
E-cigarette Use · Vaping
Primary: Participant Recruitment and Retention — 37; 31 Participants
N/A N=88 Evaluating E-Cigarette Nicotine Form, Concentration, and Flavors Among Youth
E-cigarette Use
Primary: Plasma Nicotine Concentration — 0.78; 1.08; 0.89; 1.16 ng/ml
Phase 4 N=261 Varenicline for Nicotine Vaping Cessation in Adolescents
Vaping · Nicotine Dependence
Primary: Continuous 4-week Nicotine Vaping Abstinence at End of Treatment (Weeks 9-12) — 45; 12; 5 Participants — p=<0.001
N/A N=61 A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults
Nicotine Dependence · Nicotine Addiction · Nicotine Use Disorder
Primary: Overall Treatment Satisfaction Rating — 3.8 units on a scale
Phase 2 N=40 Varenicline for Treatment of E-cigarette Dependence
Smoking Cessation
Primary: Number of Participants Abstinent From Vaping at Week 8 — 9; 6 Participants
N/A N=12 A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product
Healthy Volunteers
Primary: Nicotine Plasma Concentration — 3.6; 2.5; 2.5; 21.2 ng/ml
N/A N=40 The Acute Effect of Vaping on Food Intake
Energy Intake · Food Intake · E-Cig Use
Primary: Energy Intake — 1102.1; 1003.4; 910.4; 868.3 Kilocalories
N/A N=408 A Study to Evaluate the Safety Profile of an e-Vapour Product
Healthy Volunteers
Primary: Adverse Events — 1.60; 0.79 percentage of adverse events
N/A N=106 Goal2QuitVaping for Nicotine Vaping Cessation Among Adolescents
Depressive Symptoms · Depression · Adolescent Behavior
Primary: Mean Score of Depressive Symptoms — -9.50; -8.30 score on a scale
N/A N=19 The Cardiovascular Effects of Electronic Hookah Vaping
Endothelial Dysfunction · Inflammation · Oxidative Stress
Primary: Flow-Mediated Dilation (FMD) — 6.11; 5.89; 4.79; 7.31 percentage of arterial diameter
N/A N=480 Impact of E-Cigarette Prevention Messages on Adolescents
Vaping Behavior
Primary: Mean Susceptibility to Vaping Score — 1.91; 1.82 score on a scale
N/A N=209 A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years
Healthy Volunteers
Primary: Blood Pressure — 122.4 mmHg
N/A N=31 JUUL vs. Mod E-cigarette Study
Smoking · Tobacco Use
Primary: Choices to Smoke — 26.15; 30; 38.33 Percentage of Total Choices
N/A N=1,369 Impact of E-cigarette Device Warnings
Vaping Behaviors
Primary: Mean Vaping Quit Intentions Score — 2.5; 2.5; 2.2 score on a scale — p=<.001
N/A N=100 Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy
Tobacco Use Disorder · Smoking
Primary: Changes in the Number of Cigarettes Per Day (CPD) — 8.2; 7.3 cigarettes per day (CPD)
N/A N=350 Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures
Smoking, Cigarette
Primary: Proportion of Participants With Self-Reported 7-day Point Prevalence Abstinence From Cigarettes — 41; 33 Participants
Early Phase 1 N=11 Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study
Pulmonary Disease, Chronic Obstructive · E-cigarettes
Primary: Pulmonary Microvascular Blood Flow (PMBF), Measured on Gadolinium-enhanced MRI, Between E-cigarette Exposed and Unexposed Conditions — 74.4; 63.1 mL(blood)/min/mL(lung)…
Phase 2 N=160 A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Vaping · E-Cig Use
Primary: Percentage of Participants With Vaping Abstinence From Week 9 to 12 — 15.1; 31.8 percentage of participants — p=0.0350
N/A N=33 Assessing Electronic Cigarette Nicotine Flux
Electronic Cigarette Use
Primary: Plasma Nicotine Concentration — 2.00; 1.92; 1.64; 1.62 mg/ml
Phase 4 N=508 Research and Innovation to Stop E-cigarette/Vaping in Young Adults
Nicotine Dependence · E-Cig Use
Primary: 7-day Point Prevalence Vaping Abstinence — 55; 54; 61; 59 Participants — p=0.14
N/A N=37 Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 2.2; 1.8; 6.0; 7.1 model estimated cigarettes per day
Phase 4 N=30 Effect of Electronic Cigarette Use on Cough Reflex Sensitivity
Cough
Primary: Change in Cough Reflex Sensitivity (Log C5) — -0.29; 0.24 log C5
N/A N=29 Electronic Cigarette Use in Young Adult Men and Women
Cigarette Smoking · Tobacco Use
Primary: Contextual Factors Associated With Tobacco Use Episode Reported Via Ecological Momentary Assessment — 3; 22; 11; 12 tobacco use episodes — p=0.002
N/A N=40 Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation
Behavior, Health Risk · Implementation Science · E Cigarette Use
Primary: Engagement_remote checkin_3 — 6; 5; 6; 5 Participants — p=0.820
N/A N=1,565 Impact of Vaping Prevention Advertisements
Vaping
Primary: Mean Susceptibility to Vaping Score — 2.16; 2.21; 2.36 score on a scale
N/A N=144 Adolescent Inpatient Tobacco and ENDS Intervention
Vaping · Smoking
Primary: Self-reported 30-day Abstinence — 16; 25 Participants — p=0.91
Phase 3 N=25 Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
Smoking Cessation · Harm Reduction
Primary: Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6 — 8 Participants
N/A N=15 Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
Nicotine Dependence
Primary: Maximum Concentration of Nicotine in Plasma (Cmax) — 5.7; 11.8; 6.7; 8.1 ng/mL
N/A N=17 E-cigarettes for Harm Reduction in Adults With Asthma
Smoking · Asthma · Electronic Cigarette Use
Primary: Change in Cigarettes Per Day From Baseline to Week 8 and Week 16 — 16.34; 15.39; 9.51; 8.66 cigarettes per day — p=.004